Aclaris Therapeutics (ACRS) Expected to Announce Earnings on Wednesday

Key Points

• Aclaris Therapeutics is set to announce its Q2 2025 earnings on August 6th, with analysts predicting a loss of ($0.14) per share and revenue of $1.34 million.
• The company reported a negative net margin of 732.42% and a negative return on equity of 30.73% in its last earnings report.
• Aclaris's stock has seen significant institutional interest, with notable increases in holdings from firms like Invesco Ltd. and Goldman Sachs Group.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect Aclaris Therapeutics to post earnings of ($0.14) per share and revenue of $1.34 million for the quarter.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.07. Aclaris Therapeutics had a negative return on equity of 30.73% and a negative net margin of 732.42%. On average, analysts expect Aclaris Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aclaris Therapeutics Stock Performance

Shares of NASDAQ ACRS remained flat at $1.53 during trading hours on Friday. The company had a trading volume of 1,094,014 shares, compared to its average volume of 1,384,093. The firm has a market cap of $165.67 million, a price-to-earnings ratio of -1.10 and a beta of 0.30. The company has a 50-day moving average price of $1.51 and a two-hundred day moving average price of $1.65. Aclaris Therapeutics has a 12-month low of $1.05 and a 12-month high of $5.17.

Hedge Funds Weigh In On Aclaris Therapeutics

A number of large investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its position in shares of Aclaris Therapeutics by 29.7% during the first quarter. Goldman Sachs Group Inc. now owns 555,953 shares of the biotechnology company's stock worth $851,000 after purchasing an additional 127,366 shares in the last quarter. Millennium Management LLC increased its position in shares of Aclaris Therapeutics by 111.0% during the first quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company's stock worth $6,325,000 after purchasing an additional 2,175,101 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of Aclaris Therapeutics by 409.0% during the first quarter. Invesco Ltd. now owns 57,079 shares of the biotechnology company's stock worth $87,000 after purchasing an additional 45,864 shares in the last quarter. 98.34% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Wedbush reiterated an "outperform" rating and issued a $8.00 price target on shares of Aclaris Therapeutics in a report on Monday, June 23rd. HC Wainwright reiterated a "buy" rating and issued a $16.00 price target on shares of Aclaris Therapeutics in a report on Wednesday, June 25th. Scotiabank reduced their price objective on shares of Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating for the company in a research note on Friday, May 9th. Finally, Piper Sandler began coverage on shares of Aclaris Therapeutics in a research note on Thursday, July 10th. They issued an "overweight" rating and a $6.00 price objective for the company. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Aclaris Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $8.71.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.